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Summary
 
Using a snake toxin as a proteic antigen (Ag), two murine toxin–specific monoclonal antibod-
ies (mAbs), splenocytes, and two murine Ag–specific T cell hybridomas, we showed that solu-
ble protein A (SpA) from 
 
Staphylococcus aureus
 
 and protein G from 
 
Streptococcus 
 
subspecies, two
Ig binding proteins (IBPs), not only abolish the capacity of the mAbs to decrease Ag presenta-
tion but also increase Ag presentation 20–100-fold. Five lines of evidence suggest that this phe-
nomenon results from binding of an IBP–Ab–Ag complex to B cells possessing IBP receptors.
First, we showed that SpA is likely to boost presentation of a free mAb, suggesting that the
IBP-boosted presentation of an Ag in an immune complex results from the binding of IBP to
the mAb. Second, FACS
 
®
 
 analyses showed that an Ag–Ab complex is preferentially targeted by
SpA to a subpopulation of splenocytes mainly composed of B cells. Third, SpA-dependent
boosted presentation of an Ag–Ab complex is further enhanced when splenocytes are enriched
in cells containing SpA receptors. Fourth, the boosting effect largely diminishes when spleno-
cytes are depleted of cells containing SpA receptors. Fifth, the boosting effect occurs only when
IBP simultaneously contains a Fab and an Fc binding site. Altogether, our data suggest that sol-
uble IBPs can bridge immune complexes to APCs containing IBP receptors, raising the possi-
bility that during an infection process by bacteria secreting these IBPs, Ag-specific T cells may
activate IBP receptor–containing B cells by a mechanism of intermolecular help, thus leading
to a nonspecific immune response.
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P
 
revious studies have shown that an Ag-specific Ab can
modulate presentation of an Ag to T cells (1–5). At
least two mechanisms can be associated with these observa-
tions. First, some of the Fc
 
g
 
 receptors expressed on APCs
can mediate the internalization of the immune complex and
thus may enhance Ag presentation (6–8). Second, Ag-speci-
fic Abs can affect the processing pattern of an Ag (9, 10),
causing an enhanced or suppressed presentation of various
T cell determinants (11, 12). This raises the question of
whether components that interact with Abs, such as soluble
microbial Ig binding proteins (IBPs),
 
1
 
 can also influence
presentation of Ag–Ab complexes.
Microbial IBPs are produced by protozoa, viruses, and
both gram-positive and gram-negative bacteria (13) and
play important physiological roles (14). In particular, pro-
tein A (SpA) from 
 
Staphylococcus aureus
 
 can modify opsoni-
zation, phagocytosis, complement consumption (15, 16),
Ab-dependent cell-mediated cytotoxicity (17), and mito-
genesis (18). Molecular properties of SpA are well docu-
mented. It is a monomeric protein that can bind to an Ig
molecule, free or bound to its Ag (19–21). SpA can bind to
the Fc
 
g
 
 part of the Ab (22) through any of its five Fc
 
g
 
binding domains, called EDABC (23, 24). It can also bind
to the Fab region of an Ab via an alternative recognition
site (25–30) located in the V
 
H
 
 domain (31). This site is
present in a large proportion of IgM, IgA, and IgG F(ab
 
9
 
)
 
2
 
that are restricted to the V
 
H
 
III family in humans (32–34)
and to the S107 and J606 families in mice (35, 36). Thus,
SpA can interact with a large proportion of B cells and is
therefore considered a B cell superantigen (37, 38). As SpA
is naturally and efficiently secreted by 
 
S
 
.
 
 aureus
 
 (39–41),
we investigated its possible influence on presentation of an
Ag–Ab complex.
 
1
 
Abbreviations used in this paper:
 
 CTLL, cytotoxic T cell line; FCC, fluores-
cein-5(6)-carboxamidocaproic; hIg, human immunoglobulin; IBP, im-
munoglobulin binding protein; SAPE, streptavidin-PE; SpA, staphylo-
coccal protein A; ssp., subspecies. 
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In this study, we examined, in a murine model, the
influence of SpA on T cell presentation of Ag–Ab com-
plexes, using a snake toxin as a proteic Ag, two toxin-speci-
fic mAbs, splenocytes, and two Ag-specific T cell hybrido-
mas. We show that SpA not only abolishes the capacity of
mAbs to diminish Ag presentation but also increases Ag
presentation by 20–100-fold. In addition, we show that (i)
SpA targets Ag–Ab complex to a subpopulation of spleno-
cytes containing SpA receptors and mainly composed of B
lymphocytes; (ii) APCs that possess SpA receptors are re-
sponsible for the boosting effect; (iii) the boosting effect
occurs only when the IBP simultaneously possesses a Fab
and an Fc binding site; (iv) in the absence of its Ag, an Ab
also undergoes a SpA-specific boosted presentation. Alto-
gether, our observations suggest that SpA boosts Ag pre-
sentation by bridging an immune complex to SpA recep-
tors present at the surface of appropriate APCs. We also
show that protein G from 
 
Streptococcus 
 
subspecies
 
 
 
(ssp.)
group C, another bacterial IBP, can also boost presentation
of Ag–Ab complexes. Our observations raise the possibility
that during an infection process by bacteria secreting these
IBPs, Ag-specific T cells may activate IBP receptor–contain-
ing B cells by a mechanism of intermolecular help, thus lead-
ing to a nonspecific immune response. Several reports sug-
gest that these observations may also be extended to humans.
 
Materials and Methods
 
Proteins and Reagents
 
Protein A from 
 
S. aureus
 
, protein G from group C 
 
Streptococcus
 
ssp.
 
, the IgG binding fragment BB, and protein G
 
9
 
 were purchased
from Sigma Chemical Co. ZZ was expressed and purified as previ-
ously described (49). Toxin 
 
a
 
 was purified from 
 
Naja nigricollis
 
venom (Pasteur Institute, Paris, France). Purity of the toxin was as-
sessed by both reverse phase HPLC and isoelectric focusing. Biorex
70 and Bio-Gel P2 were obtained from Bio-Rad Labs. 
 
N
 
-succin-
imidyl-3(2-pyridyldithio) proprionate (SPDP) was purchased from
Pharmacia, and 
 
N
 
-succinimidyl 4-(
 
N
 
-maleimidomethyl) cyclohex-
ane-1-carboxylate (SMCC) was purchased from Pierce Chemical
Co. 
 
N
 
-hydroxysuccinimidyl-fluorescein-5(6)-carboxamidocaproate
(NHS–FCC) was obtained from Sigma Chemical Co. The HPLC
C18 column (25 cm 
 
3
 
 10 mm) was from Vydac. All solvents were
obtained from Merck and used without further purification. mAb
B220, Mac-2, anti-CD4, and anti-CD8 were from the American
Type Culture Collection. Streptavidin-PE (SAPE) was purchased
from Caltag Labs.
 
Chemical Modification of Proteins
 
Chemical Modification with NHS–FCC and NHS–biotin.
 
SpA
was dialyzed overnight at 4
 
8
 
C against PBS before its modification
with NHS–FCC. 52 nmol of SpA was subsequently incubated for
1 h at room temperature with 10
 
3
 
 excess NHS–FCC. The reac-
tion mixture was filtered through a Sephadex G15 column (26 
 
3
 
1.5 cm) equilibrated in 50 mM phosphate buffer, pH 7.2. The
protein that eluted in the void volume was used without further
purification. 73.5 nmol of toxin 
 
a
 
 was modified with 735 nmol
of NHS–FCC according to the same protocol. The procedure
used for the biotinylation of protein G was similar to that de-
scribed for NHS–FCC.
 
Covalent Coupling of Toxin 
 
a
 
 to mAb MST2
 
For the covalent coupling of toxin 
 
a
 
 to MST2, we used a
modified procedure of the protocol previously described for cou-
pling of toxin 
 
a
 
 to peroxidase (42).
 
Monothiolation of Toxin 
 
a
 
.
 
200 
 
m
 
l of SPDP (17 
 
m
 
M) in abso-
lute ethanol was added to 3.38 
 
m
 
mol of toxin 
 
a
 
 in 1.8 ml of 0.1 M
phosphate buffer, pH 7.5, containing 0.1 M NaCl. The mixture
was stirred for 30 min at room temperature. The reaction mix-
ture was filtered through a Bio-Gel P2 column (26 
 
3
 
 1.5 cm)
equilibrated in 10% acetic acid. The protein which eluted in the
void volume was freeze dried. The modified protein was dis-
solved in 1 ml of 0.05 M ammonium acetate, pH 7.1, and applied
onto a Bio-Rex 70 column (70 
 
3
 
 2.5 cm) equilibrated in the
same buffer. The toxin was eluted with a linear gradient of 0.05–
0.4 M ammonium acetate, pH 7.1. Fractions containing mono-
modified derivatives were roughly identified by analogy with the
elution profile previously obtained with monoacetylated deriva-
tives. The modified amino groups were unambiguously identified
by determination of the affinities of each derivative for two
toxin-specific mAbs. Each derivative was rechromatographed on
a C18 10-mm Vydac column equilibrated in water containing
0.1% TFA. The derivatives were eluted by using acetonitrile as
secondary solvent. Elution was over a linear gradient of 0–50%
acetonitrile. Each derivative that was freeze dried had incorpo-
rated a 2-pyridyl-dithiopropionate moiety on a single lysine.
 
Incorporation of Maleimido Groups into mAb MST2.
 
5.5 
 
m
 
l of
dimethylformamide containing 83 nmol of SMCC was added to
8.3 nmol of MST2 dissolved in 312 
 
m
 
l of 0.1 M phosphate buffer,
pH 7, containing 0.1 M NaCl. The mixture was left for 1 h with
stirring at room temperature. The reaction mixture was then fil-
tered through a Sephadex G15 column (20 
 
3
 
 0.5 cm) equili-
brated in 0.1 M phosphate buffer, pH 6, containing 0.1 M NaCl.
 
Coupling Procedure.
 
The coupling reaction was performed in
three steps. (i) The extra disulfide bond at Lys 27 was reduced.
8.3 nmol of the derivative was dissolved in 200 
 
m
 
l of 0.1 M ace-
tate buffer, pH 4.5, containing 0.1 M NaCl and 25 mM dithio-
threitol. The mixture was left under stirring at room temperature
for 20 min, and the solution was filtered through a Sephadex G15
column (20 
 
3
 
 0.5 cm) equilibrated in 0.1 M phosphate buffer,
pH 6.1, containing 0.1 M NaCl. The monothiolated toxin eluted
in the void volume. (ii) (27-N
 
e
 
 mono thio-propionyl-lysine)–
toxin 
 
a
 
 (8.3 nmol) was reacted with maleimido MST2 (8.3 nmol)
overnight at 4
 
8
 
C. Uncoupled toxin 
 
a
 
 was removed by affinity
chromatography on a Sepharose–protein G column. The conju-
gate was then concentrated using a Centricon
 
®
 
 10 and stored at
 
2
 
20
 
8
 
C with 0.1% BSA.
 
ELISA
 
Microtiter ELISA plates were coated overnight with either
0.3% BSA or polyclonal human (h) IgMs (1 
 
m
 
g/well) in 0.05 M
phosphate buffer, pH 7.4. Plates were then saturated with 0.3%
BSA in 0.1 M phosphate buffer, pH 7.4. Dilutions of biotinylated
toxin 
 
a
 
, M
 
a
 
2-3, ZZ, and BB were performed in 0.1 M phos-
phate buffer, pH 7.4, containing 0.1% BSA. For the assessment of
the binding of M
 
a
 
2-3 to IgM-coated plates, the mAb (3 nM) was
incubated overnight at 4
 
8
 
C in BSA-coated plates in the presence
or absence of ZZ or BB (8 nM for each SpA derivative). The in-
cubated solutions were then transferred into IgM-coated plates
and left at room temperature for 4 h. The wells were then washed
five times with 0.01 M phosphate buffer, pH 7.4, containing
Tween 20, and a F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgG peroxidase conju-
gate (Immunotech) was added and incubated for 30 min. After ex- 
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tensive washings, 2,2
 
9
 
-azino-bis(3-ethylbenz-thiazoline-6-sulfonic
acid) (ABTS) was added, coloration was developed for 30 min, and
the resulting absorbance was measured at 414 nm. For the assess-
ment of the binding of biotinylated toxin 
 
a
 
 to IgM-coated plates,
M
 
a
 
2-3 and biotinylated toxin 
 
a
 
 were incubated overnight at 4
 
8
 
C
in BSA-coated plates in the presence or absence of ZZ or BB.
The incubated solutions were then transferred into IgM-coated
plates and left at room temperature for 4 h. The wells were washed,
and a streptavidin peroxidase conjugate (Immunotech) was added
and incubated for 30 min. ABTS was used as a substrate as de-
scribed above.
 
T Cell–stimulating Assay
 
All experiments were performed using DCCM1 (Biological In-
dustries) as a synthetic culture medium, in the absence of FCS.
Fixed or serial dilutions of the different Ags were preincubated in
microculture wells for one night at 4
 
8
 
C. 5 
 
3
 
 10
 
5
 
 splenocytes per
well were then added, along with 5 
 
3
 
 10
 
4
 
 of either T1B2 or T1C9
hybridoma. Cells were cultured for 24 h at 37
 
8
 
C in a humidified 7%
CO
 
2
 
 atmosphere. For the assessment of the presenting capacity of
SpA-specific cells, various amounts of splenocytes, splenocytes en-
riched with SpA-specific cells, or splenocytes depleted of SpA-spe-
cific cells were added to the wells in the presence of 5 
 
3
 
 10
 
4
 
 T1B2.
The presence of IL-2 in culture supernatants from T cell
hybridoma and bulk culture was evaluated by determining the
proliferation of an IL-2–dependent cytotoxic T cell line (CTLL)
using methyl [
 
3
 
H]TdR (5 Ci/mmol; CEA). The data are ex-
pressed in cpm.
 
Flow Cytometric Analysis
 
Binding to Splenocytes. 
 
Biotinylated toxin 
 
a
 
 (0.7 
 
m
 
M) was
incubated for one night at 4
 
8
 
C in the presence or absence of SpA
and M
 
a
 
1 (0.6 and 0.1 
 
m
 
M, respectively). Splenocytes (5 
 
3
 
 10
 
5
 
cells) were then added and incubated for 30 min at 4
 
8
 
C in PBS/
0.5% BSA. Cells were washed three times and incubated for 30
min at 4
 
8
 
C with SAPE (6 
 
m
 
g/ml). After three washes, 5,000
viable cells were analyzed on a FACS
 
®
 
 (Becton Dickinson). The
binding of SpAF to splenocytes was assessed by incubating 5 
 
3
 
10
 
5
 
 cells for 30 min at 4
 
8
 
C with 50 
 
m
 
l SpAF (0.6 
 
m
 
M final) in the
presence or absence of 10
 
3
 
 excess unlabeled SpA. After three
washes, 5,000 viable cells were analyzed on a FACS
 
®
 
. For the as-
sessment of the binding of the two IBPs to splenocytes, biotiny-
lated protein G (0.2 
 
m
 
M final) was incubated for 30 min at 48C
with 5 3 105 cells in the presence or absence of SpAF. Spleno-
cytes were subsequently washed three times and incubated for 30
min at 48C with SAPE (6 mg/ml). After three washes, 5,000 via-
ble cells were analyzed on a FACS®.
Cell Sorting of Splenocytes.  Cells were incubated for 30 min at
48C in the presence of SpAF. After three washings, splenocytes
were filtered through nylon and sorted at 2,000 cells/s under sterile
conditions on an EPICS V flow cytometer (Coulter) using a
76-mM nozzle and the 488-nm line of an argon laser set at 300
mW. PBS was used as a sheath fluid. The sorting criteria were nor-
mal forward-angle light scatter and bright fluorescein fluorescence
(515–560 nm) taken on a log scale; z2% of cells were positive.
Binding to Cell-sorted Splenocytes. Biotinylated toxin a (0.7 mM)
and SpA (0.6 mM) were incubated for one night at 48C in the
presence or absence of Ma1 (0.1 mM). 105 splenocytes, SpA un-
bound splenocytes, or SpA-bound cell–enriched splenocytes were
then added and incubated for 30 min at 48C in PBS/0.5% BSA.
Cells were washed three times, and binding to cells was analyzed
as described above. To determine the type of cells bound by SpAF,
SpA-bound cell–enriched splenocytes were incubated for 30 min
at 48C with mAb–B220, Mac-2, anti-CD4, and anti-CD8, respec-
tively (0.1 mM final for each). Cells were washed three times, and
binding to cells was analyzed as described above.
Results
SpA Enhances Presentation of Ag–Ab Complex. We inves-
tigated the influence of SpA from S. aureus on presentation of
an Ag–Ab complex to Ag-specific T cells. We used a snake
toxin, toxin a (43), as an Ag, two toxin a–specific T cell hy-
bridomas, called T1C9 and T1B2 (44), and two IgG2a toxin
a–specific mAbs, called Ma1 (45) and Ma2-3 (46), whose
epitopes are topographically unrelated to each other. Serial
dilutions of toxin a were preincubated overnight at 48C in
the presence of fixed quantities of a toxin-specific mAb (Ma1
or Ma2-3) and SpA before addition of the appropriate T cells
and splenocytes from BALB/c mice. Secretion of IL-2 was
determined 24 h later. As shown in Fig. 1, the capacity of
toxin a to stimulate T1B2 and T1C9 in the presence of sple-
nocytes decreased when the Ag was incubated with either
Ma1 (Fig. 1, A and B) or Ma2-3 (Fig. 1 C). However, the
suppressing effect caused by the two toxin-specific mAbs not
only vanished in the presence of soluble SpA, but the efficacy
of Ag presentation dramatically increased. Fig. 1 shows that
20–100-fold lower amounts of toxin a sufficed to cause se-
cretion of the same amounts of IL-2 when the Ag was incu-
bated with both toxin-specific mAbs and SpA. Therefore, the
presence of an Ig-binding protein can specifically enhance
presentation of an Ag complexed to an Ag-specific Ab.
In these experiments, we used relatively high propor-
tions of SpA and mAbs (0.2 mM). Nevertheless, when their
concentrations decreased to 4 nM and 2 nM, respectively,
being thus probably closer to physiological conditions, a
potent boosting effect remained observable (Fig. 1 D). It is
notable that, in these experiments, the initial suppressing
effect of the mAb apparently disappeared (Fig. 1 D). This is
no surprise, as the ratio of concentrations of mAb (2 nM)
to antigen (0.1 mM) was low and, as a result, the presenta-
tion associated with the free toxin dominated and over-
shadowed the inhibiting effect of the mAb. The same phe-
nomenon was observed in all experiments in which the
toxin concentration was higher than that of the antibody
(see below).
This is not the first time that an Ag presentation has been
shown to be affected by mAbs. In particular, presentation
of tetanus toxin was shown to increase or decrease in the
presence of some specific mAbs (11, 12). In our study, we
observed only a decrease in presentation by both toxin-speci-
fic mAbs, although they bound to topographically unre-
lated epitopes (45, 46). This result might be associated with
the small size (6.8 kD) of the antigen, whose mAbs cover a
large proportion of the toxin surface and are thus likely to
interfere with presentation of the toxin T cell epitopes, lo-
cated between residues 24–41 and 32–49 (44).
It was previously shown that when SpA is expressed at
the surface of Staphylococcus or coupled to Sepharose, it can
exert a mitogenic stimulating effect (18, 47). To rule out1220 Boosting of Antigen Presentation by Immunoglobulin Binding Proteins
the possibility that the SpA-specific boosting phenomenon
described above was related to such a nonspecific property,
various controls were performed. First, in the absence of
any mAbs, Ma1, or Ma2-3, the toxin a stimulation effi-
cacy was unaffected by SpA (Fig. 1, A and B). Second, in
the absence of toxin a, no IL-2 stimulation was triggered
by soluble SpA and Ma1 (Fig. 1, A and B). Third, SpA did
not modify Ag presentation when the Ab was an unrelated
IgG2a (Fig. 1 D). Fourth, no stimulation occurred when
splenocytes and T1B2 were incubated separately with SpA,
toxin a, and Ma1 (data not shown). Therefore, besides the
necessary appropriate immune cells, three additional com-
ponents were absolutely required for the boosting effect to
be observable: the Ag, an Ag-specific Ab, and soluble SpA.
The SpA-boosted Presentation of Ag Remains MHC Re-
stricted. The presentation of free toxin a to T1B2 and
T1C9 is restricted to I-Ad and I-Ed, respectively (44). We
investigated whether or not this MHC restriction was still
associated with the SpA-boosted presentation of the toxin
using splenocytes from D2GD mice, which express I-Ad
and I-Eb molecules. We observed that the capacity of toxin
a to stimulate T1B2 was boosted when the toxin was added
Figure 1. T cell presentation of toxin a in the presence of soluble SpA. Toxin a (Alpha) was serially diluted and incubated overnight at 48C in the
presence or absence of fixed concentrations of SpA and either mAb Ma1 (0.2 mM final) or Ma2-3 (0.1 mM final). 5 3 105 splenocytes from BALB/c
mice were then added to each well in the presence of 5 3 104 of either T1B2 (A) or T1C9 (B and C). Cells were cultured for 24 h at 378C, and IL-2 se-
cretion was subsequently determined by CTLL assay. The experiments shown in A were repeated in the presence of variable concentrations of SpA and
a fixed concentration of Ma1 (2 nM final; D). In this experiment, a control was performed using an unrelated IgG2a and SpA (0.1 mM final for each).
Figure 2. T cell presentation
of toxin a in the presence of
toxin-specific antibody and SpA
is MHC restricted. Toxin a was
serially diluted and incubated
overnight at 48C in the presence
or absence of fixed concentra-
tions of SpA and Ma1 (0.1 mM
final for each protein). 5 3 105
of splenocytes from D2GD mice
were then added to each well in
the presence of 5 3 104 of either
T1B2 (A) or T1C9 (B). T cell
stimulation was assessed as in the
Fig. 1 legend.1221 Léonetti et al.
concomitantly with both the mAb and SpA (Fig. 2 A),
whereas under the same experimental conditions, T1C9 was
not stimulated (Fig. 2 B). Therefore, the SpA-dependent
boosting presentation of an Ag complexed to an Ag-specific
Ab remains MHC restricted and is not related to the MHC-
independent genetic background of BALB/c mice.
Ag–Ab Complexes Are Targeted to APC Possessing SpA Re-
ceptors. What are the mechanisms that may account for an
SpA-dependent boosting presentation of an Ag complexed
to an Ag-specific Ab? As already mentioned, SpA possesses
multiple Ig binding sites (23, 24) and therefore could bind
simultaneously to several immune complexes, thus generat-
ing an artificial concentration effect. In other words, incu-
bation of stoichiometric concentrations of Ab and SpA could
favor formation of heterogeneous multimolecular com-
plexes, and those possessing several toxin molecules could
predominantly generate the boosting effect. To examine
such a possibility, we incubated overnight a constant con-
centration of SpA with varying dilutions of toxin a and
either a fixed concentration of Ma1 or varying concentra-
tions of Ma1 so that the ratios of SpA/Ma1 were equal to
1.5, 4.5, 13.5, 40.5, 121.5, or 364.5 for the first to the sixth
dilution, respectively. Thus, in each toxin dilution, at most
one molecule of the immune complex should have bound
to one SpA molecule. As shown in Fig. 3, T cell presenta-
tion evolved similarly with toxin dilution, irrespective of
whether the concentrations of Ma1 were fixed or variable.
Therefore, the observed boosted T cell stimulation seems
to be unrelated to the number of Ab–Ag molecules associ-
ated to an SpA molecule.
Another explanation that may account for the SpA-
enhanced presentation of an Ag is that SpA targets Ag–Ab
complexes to APCs that possess SpA receptors on their sur-
faces. To investigate this possibility, we performed a series
of FACS® analyses. At first, we examined the direct binding
of SpA to splenocytes using SpA labeled with FCC (SpAF).
As shown in Fig. 4, E–G, labeled SpA binds specifically to a
subpopulation of splenocyte cells. We then investigated the
binding of the Ag on splenocytes using SpA, a toxin-speci-
fic mAb (Ma1), and the biotinylated toxin a, which was de-
tected by SAPE. When the biotinylated toxin a was added
alone, ,0.5% of splenocytes were labeled (Fig. 4 A). The
same result was obtained when SpA (Fig. 4 B) or Ma1 (Fig.
4 C) was added separately. In sharp contrast, when the bio-
tinylated toxin was concomitantly incubated with Ma1
and SpA, the proportion of labeled cells increased to nearly
3% (Fig. 4 D). These findings support the view that spleno-
cytes possess SpA-specific cells and that an Ag–Ab complex
binds to this subpopulation.
To further validate this conclusion, we sorted SpAF-
labeled splenocytes (2% of the whole population) and in-
vestigated the binding of the biotinylated Ag to this popu-
lation enriched in SpA-specific cells. 32% of the positively
sorted splenocytes were effectively labeled with SpAF (Fig.
5 E, bottom right). In the absence of both SpA and Ma1,
quite a small proportion of these cells were labeled with the
Figure 3. T cell presentation of toxin a in the presence of fixed or de-
creasing concentrations of Ma1. Toxin a was serially diluted and incu-
bated overnight at 48C in the presence or absence of fixed concentrations
of SpA (0.3 mM final) and either serial dilutions of Ma1 or a fixed
amount of mAb (0.2 mM final). 5 3 105 splenocytes from BALB/c mice
were then added to each well in the presence of 5 3 104 T1B2. T cell
stimulation was then assessed as previously described.
Figure 4. Binding of the immune complex and SpA on splenocytes. Biotinylated toxin a (Alphab) was incubated overnight at 48C (A), in the presence
of a fixed concentration of SpA (B), Ma1 (C), or both (D). Splenocytes (5 3 105 cells) were added and incubated for 30 min at 48C. Binding of biotiny-
lated toxin a to cells was assessed using SAPE. FACS® analyses E–G show splenocytes (5 3 105 cells) incubated for 30 min at 48C without SpAF (E), in
the presence of SpAF alone (F), or SpAF diluted with a 103 excess unlabeled SpA (G).1222 Boosting of Antigen Presentation by Immunoglobulin Binding Proteins
biotinylated toxin (Fig. 5 E, top right). In contrast, when
both Ma1 and SpA were present, nearly 60% of the SpAF-
labeled cells were labeled with the biotinylated Ag (Fig. 5 F,
top right). However, a proportion of SpAF-labeled spleno-
cytes were not labeled with the biotinylated toxin, even
when both the mAb and SpA were present in the medium
(Fig. 5 F, bottom right). No definite explanation presently
accounts for this observation. Control experiments were
carried out with the population of negatively sorted cells,
which contained only 0.4% of SpAF-labeled cells (Fig. 5 C,
bottom right). Only 0.6% of the depleted splenocytes were
labeled with the biotinylated Ag in the presence of the Ab
and SpA (Fig. 5 D, top left and top right), and this value
did not increase to more than 2.5% when the splenocytes
were unsorted (Fig. 5 B, top left). Altogether, these experi-
ments provide direct evidence that in the presence of SpA,
an Ag–Ab complex is preferentially targeted to a particular
subpopulation of splenocytes that possess SpA receptors.
To identify the cell types that predominantly populated
splenocytes enriched in sorted SpAF-labeled cells, we used
four biotinylated mAbs (mAb B220, mAb Mac 2, mAb
GK1.2, and mAb H35) and SAPE. As shown in Fig. 5 G, a
shift in fluorescence intensity was observed with the B cell
marker, whereas no shift was observed using macrophage,
CD4, and CD8 cell surface markers (Fig. 5, H–J). There-
fore, SpAF-bound cells are mainly composed of B cells.
The Boosted Presentation Requires APCs Possessing SpA Re-
ceptor. We investigated the ability of both unsorted sple-
nocytes (S) and splenocytes enriched with (ES) or depleted
of (DS) SpAF-bound cells to stimulate T1B2 in the pres-
ence of toxin a alone or in combination with both SpA and
Ma1. As shown in Fig. 6 A, 104 splenocytes enriched with
SpA receptor–possessing cells were z10-fold more efficient
than 104 unsorted splenocytes at boosting toxin a presenta-
tion in the presence of Ma1 and SpA. In contrast, 105 un-
sorted splenocytes were z10-fold more efficient than 105
splenocytes depleted of SpA receptor–containing cells (Fig.
6 B). The observed differences in efficiency are not related to
a modification of the processing efficiency of cells treated
with SpAF during the sorting experiments, as control experi-
ments showed that splenocytes enriched with SpA recep-
tor–containing cells were equally as efficient as unsorted
splenocytes at presenting toxin a alone (Fig. 6). Further
demonstration that positively sorted cells are more efficient
than unsorted cells, which in turn are more efficient than
the negatively sorted splenocytes, is also shown in Fig. 6 C,
where stimulation of T1B2 by the Ab–Ag complex in the
presence of SpA is shown as a function of the number of
cells. Therefore, the subpopulation of splenocytes possess-
ing SpA receptors is mainly responsible for the capacity of
SpA to boost the T cell stimulation of Ag–Ab complex.
SpA Receptors May Be Surface Immunoglobulins. The above
data indicated that the Ag–Ab complexes are targeted to
SpA receptors present at the surface of APCs containing
predominantly B cells. In other words, the boosting effect
can be interpreted as resulting from the formation of com-
plexes that consist of a SpA receptor bound to SpA, which
in turn is bound to Ab–Ag complex. To investigate the
possibility that the SpA receptors may be surface Igs, we
proceeded as follows. First, we selected two SpA deriva-
tives which differ in their recognition specificity toward
Igs. One of them is composed of two B domains (BB), and,
like SpA, recognizes the Fab region of IgMs and IgGs as
well as the Fcg part of IgG (48). The other derivative is ZZ
(Z is a mutant of domain B [49]) and binds to the Fcg part
of IgG but very weakly to the Fab region (50). Second, we
examined the binding of either a mouse mAb or biotiny-
lated toxin a to hIgM-coated plates. As shown in Fig. 7 A
(left), the mouse IgG2a mAb Ma2-3 can bind to coated
hIgMs in the presence of BB but not in the presence of
ZZ. Furthermore, the presence of Ma2-3 and BB is a pre-
requisite for the binding of biotinylated toxin a to coated
hIgMs (Fig. 7 A, right). Therefore, formation of a ternary
complex, IgM–SpA derivative–IgG, or a quaternary com-
Figure 5. Binding of toxin a on cell-sorted splenocytes. Biotinylated toxin a and SpA were incubated overnight at 48C with (B, D, and F) or without
(A, C, and E) Ma1. 105 unsorted splenocytes (A and B), splenocytes depleted of cells labeled with SpA–FCC (C and D), or splenocytes enriched in cells
labeled with SpA–FCC (E and F) were added and incubated for 30 min at 48C. Binding of biotinylated toxin a to cells was assessed using SAPE. Analyses
G–J show characterization of splenocytes enriched in cells labeled with SpAF, using biotinylated mAbs B220, Mac-2, GK1.2, and H35 (G, H, I, and J,
respectively). 1223 Léonetti et al.
plex, IgM–SpA derivative–IgG–Ag, is possible, provided
that the derivative can bind to both IgG and IgM. In addi-
tion, the VH domain of Ma2-3 is coded by the VH germline
gene J558 (51), a characteristic that precludes the Fab of this
IgG to bind SpA and BB (35, 36). As a result, this IgG can be
recognized only through its Fcg. Therefore, the complex
observed in the ELISA consists of an IgM bound by its Fab
to BB, which in turn binds to the Fcg region of Ma2-3.
Third, we investigated the effect of the two SpA deriva-
tives on the labeling of splenocytes from BALB/c mice by a
mouse IgG–FITC. In these unpublished experiments, we
observed that 10.8% of the splenocytes were bound by the
mouse IgG2a–FITC, a proportion which increased to
23.8% in the presence of BB and decreased to 6.4% in the
presence of ZZ. Fourth, we investigated the capacity of BB
and ZZ to boost the presentation of the Ma2-3–toxin
complex using T1C9 and splenocytes. As shown in Fig. 7
B, a boosting effect is observed when the Ab–Ag complex
is incubated in the presence of BB but not in the presence
of ZZ. Thus, the boosting effect requires that the SpA de-
rivative possesses both a binding site to the Fcg region of
Ma2-3 and a binding site to the Fab of Igs, strongly sug-
gesting that the BB–Ma2-3–Ag complex is targeted to the
Fab region of surface Igs of APCs.
The Presentation of an Immune Complex Is Also Boosted by
Protein G. We investigated whether a bacterial IBP other
than SpA could also trigger a boosting effect. Several of the
above experiments were therefore repeated using protein G
from Streptococcus ssp. group C (52), which contains both a
Fab binding site and an Fcg binding site (53, 54). As shown
in Fig. 8 A, protein G boosted presentation of toxin a to
T1B2 only when the toxin, Ma2-3, and protein G were
concomitantly added to appropriate immune cells. In con-
trast, the boosting effect was not observed with protein G9,
a protein G derivative that binds exclusively to the Fcg of
Igs (55). Therefore, these data suggest that the boosted pre-
Figure 6. T cell presentation of toxin a in the presence of cell-sorted splenocytes.
Toxin a was serially diluted and incubated overnight at 48C in the presence or absence
of fixed concentrations of SpA and Ma1 (0.1 mM final concentration for both). Then,
the different mixtures were incubated in the presence of T1B2 (5 3 104 cells) and (A)
104 APCs consisting of either splenocytes enriched in SpA specific cells (ES) or unsorted
splenocytes (S); or (B) 105 APCs consisting of either splenocytes depleted of SpA-specific
cells (DS) or unsorted splenocytes (S). C shows the stimulation of T1B2 in the presence
of variable numbers of unsorted, positively sorted, and negatively sorted splenocytes, and
a fixed concentration of toxin a (30 nM), Ma1 (0.1 mM), and SpA (0.1 mM).
Figure 7. Effect of two SpA de-
rivatives on the binding to coated
hIgMs and on the T cell presenta-
tion of toxin a. (A) Ma2-3 was
incubated overnight in the pres-
ence or absence of fixed concen-
trations of toxin a biotinylated at
the NH2 terminus (Alphabiot) and
either ZZ or BB in BSA-coated
microwell plates. The solutions
were transferred in hIgM-coated
plates. Binding of Ma2-3 to the
wells was determined using a goat
anti–mouse IgG peroxidase conju-
gate (GAM–PO), whereas bind-
ing of biotinylated toxin a was de-
termined using a streptavidin peroxidase conjugate (SA–PO). (B) Toxin a (alpha) was serially diluted and incubated overnight at 48C in the presence or
absence of mAb Ma2-3 (25 nM final) and either ZZ or BB (0.1 mM final for each derivative). 5 3 105 splenocytes from BALB/c mice were then added
to each well in the presence of 5 3 104 T1B2. T cell stimulation was assessed as previously described.1224 Boosting of Antigen Presentation by Immunoglobulin Binding Proteins
sentation of an Ab–Ag complex results from a targeting by
protein G to the Fab region of surface Igs of APCs. This
raises the question of whether SpA and protein G recognize
the same APC subpopulation. To approach this question,
we performed FACS® analyses using both biotinylated pro-
tein G and SpAF. As shown in Fig. 8, protein G (B3, top left)
and SpAF (B2, bottom right) bind to approximately the
same proportion of the whole splenocyte population. Fur-
thermore, the data presented in Fig. 8 (B4) suggest that SpA
and protein G may recognize different splenocyte subpopu-
lations. However, as we observed a slight increase in the up-
per right area of B4, we cannot preclude that a proportion of
cells recognized by SpA and protein G are the same.
SpA May Also Boost T Cell Presentation of a Free Ab.
The view that emerges from the above data is that presen-
tation of an Ag is boosted in the presence of an Ag-specific
Ab as a result of the targeting of the complex by an IBP to
APCs that contain IBP receptors. According to this scenario,
both the mAb and SpA should also undergo a boosted pre-
sentation. This was demonstrated earlier to be the case for
SpA (56). To provide evidence that it is also the case for
the mAb, one would need mAb-specific T cells; however,
they were unavailable in our laboratory. To overcome this
difficulty, we used the toxin a–specific T1B2 to tentatively
monitor the presentation of an mAb that was selected for
its inability to recognize toxin a (57). This mAb, an IgG1
called MST2, was covalently linked to toxin a, which be-
came, therefore, a label to probe the presentation of MST2.
As shown in Fig. 9, the MST2–toxin a couple was effi-
ciently presented to T1B2, and its presentation was clearly
boosted by SpA. As a control, no such boosting effect was
observed when the free toxin a was incubated with both
the uncoupled MST2 and SpA (not shown). Therefore,
only the toxin that was covalently linked to the Ab under-
went a boosted presentation. This effect most probably re-
flects a boosting effect of the Ab itself. We conclude, there-
fore, that the boosting presentation of an Ab–Ag complex,
as previously perceived via the stimulation of the Ag, re-
flects an increased presentation of both the Ag and Ag-speci-
fic Ab, a finding in agreement with the proposed scenario
that an immune complex may be targeted by SpA to APC
containing SpA receptors.
Discussion
Using a snake toxin as an Ag and two toxin-specific
mAbs (Ma1 and Ma2-3), we showed that two soluble
bacterial IBPs, SpA and protein G, dramatically increase the
Ag-specific T cell stimulation of Ag–Ab complex. These
findings are in sharp contrast to the observation that, in the
absence of IBP, either of the Ag-specific mAbs inhibits pre-
sentation of the Ag.
A number of observations cast some light on the origin
of this IBP-dependent boosting phenomenon. Thus, for
the boosted presentation of the Ag to be seen, the Ag, an
Ag-specific Ab, and an IBP, SpA or protein G, are abso-
lutely required. As SpA is likely to boost presentation of a
free Ab, we propose that the SpA-dependent boosted pre-
sentation of an immune complex, as perceived through pre-
sentation of its Ag, results from the binding of SpA to the
Ab of the immune complex. Three lines of evidence indi-
cate that the Ag-boosted presentation may result from
binding of a ternary complex SpA–Ab–Ag to B cells con-
taining SpA receptors. First, FACS® analyses demonstrated
Figure 8. T cell presentation
of toxin a in the presence of
protein G from Streptococcus ssp.
(A) Toxin a (alpha) was serially
diluted and incubated overnight
at 48C in the absence or pres-
ence of fixed concentrations of
mAb Ma2-3 (25 nM final) and
protein G or protein G9 (0.1
mM final concentration for each
derivative). 5 3 105 splenocytes
from BALB/c mice were then
added to each well in the pres-
ence of 5 3 104 T1B2. Cells
were cultured for 24 h at 378C,
and IL-2 secretion was subse-
quently determined by CTLL
assay. (B) Splenocytes (5 3 105
cells) were incubated in the absence of IBP (B1) or presence of biotinylated protein G (protGbiot; B2), SpA–FCC (B3), or both (B4) for 30 min at
48C. Cells were all incubated with SAPE and analyzed by flow cytometry.
Figure 9.  Boosted presenta-
tion of MST2, an mAb which
does not recognize toxin a as
an antigen. In the absence of
MST2-specific T cell hybrid-
oma, we took advantage of the
availability of T1B2 and coupled
MST2 covalently to toxin a,
which, therefore, was a labeling
probe to monitor the presenta-
tion of the mAb. The covalent
MST2–toxin a complex (called
MST2-alpha) was serially diluted and incubated overnight at 48C in the
presence or absence of 0.2 mM SpA. 5 3 105 splenocytes from BALB/c
mice were added to each well in the presence of 5 3 104 T1B2. Cells
were cultured for 24 h at 378C, and IL-2 secretion was subsequently de-
termined by CTLL assay.1225 Léonetti et al.
that an Ag–Ab complex is preferentially targeted by SpA to
a subpopulation of splenocytes possessing SpA-specific recep-
tors and mainly composed of B cells. Second, the boosted
presentation further increased when splenocytes were en-
riched in cells containing SpA-specific receptors. Third, the
boosting effect largely decreased when APCs were depleted
of cells containing SpA-specific receptors. Altogether, these
observations suggest that the two soluble IBPs can bridge
an immune complex to IBP receptors present at the surface
of a particular subpopulation of APCs, thus enhancing en-
docytosis and presentation of the Ag.
For SpA to bridge an immune complex to SpA recep-
tors, appropriate binding sites must exist on the Ag–Ab
complex. It is known that SpA can interact with the Fcg
region of mouse IgGs without impairing the binding of the
Ags to their paratopes (19). In addition, SpA can bind to an
alternative site located within the Fab domain of some mouse
Igs (25, 29) that is coded by VH families S107 or J606 (35,
36). The VH domain of Ma2-3, one of the two toxin-speci-
fic mAbs that triggered the boosting effect, is coded by the
VH germline gene J558 (51), whose gene product is, there-
fore, not recognized by SpA (35, 36). Thus, the Fcg region
of Ma2-3 and perhaps of Ma1, whose amino acid sequence
is still unknown, are likely to be responsible for the interac-
tion of the immune complex with SpA.
For SpA to bridge the Ab–Ag complexes to APCs, these
cells must also possess appropriate SpA receptors. Four lines
of evidence suggest that these receptors are surface Igs and
most probably IgMs. First, we observed that the quaternary
complex IgM–SpA (or BB)–Ma2-3–Ag can occur in vitro.
Second, binding of a soluble IgG to splenocytes is increased
only in the presence of an IBP derivative that possesses the
capacity of binding concomitantly to Fab and Fcg moieties.
Third, for the boosting effect to be observed, an IBP with
the same characteristics is also strictly required. Fourth, SpA
preferentially targets Ab–Ag complex to a subpopulation of
B cells. Because the surface IgMs offer an alternative binding
site on the Fab domain, we suggest that they constitute the
most plausible SpA receptors. Other possible SpA receptors
are the Igs bound in vivo to FcRs present at the surfaces of
macrophages (58). Although we detected no macrophages
in the subpopulation of splenocytes enriched in cells con-
taining SpA receptor, we cannot rule out their participation
in the boosting effect. Therefore, our findings are compati-
ble with the view that SpA may link the Fcg part of the Ab
moiety of an immune complex to cell surface, SpA-specific
receptor structures such as IgMs present at the surface of a
subpopulation of murine splenocytes.
Protein G from Streptococcus ssp. also efficiently boosts the
presentation of Ag in immune complexes. Like SpA, pro-
tein G binds to the Fc region of IgGs in the Cg2–Cg3
interface (53, 54), their respective epitopes partially over-
lapping (59). Unlike SpA, however, protein G binds to Fab
regions of IgG via the CH1 domain (60, 61) and not to
IgMs (52). Therefore, if soluble protein G acts, like SpA, as
an enhancer of immune complex presentation, its bridging
capacity is likely to be different. Presumably, protein G pre-
dominantly focuses immune complexes to APCs carrying
IgGs.
Several lines of evidence, mostly taken from the litera-
ture, indicate that SpA may react similarly with both human
and mouse Igs. First, hIgs bind at two independent sites on
SpA (14, 26–28, 30). Second, mouse Igs S107 and J606 are
related to the human VH genes of family 3 (62), and several
works have shown that hIgG F(ab9)2 and hIgM reacting
with SpA derive from the VHIII family but do not have
markers for other families (32–34). More precisely, 16/26
potentially functional germline VHIII genes encode SpA re-
activity (63, 64). Third, SpA–Sepharose or SpA-containing
S. aureus can stimulate B cells expressing VH gene segments
encoded by a set of genes belonging to the VHIII family
(47). Fourth, as reported above, the quaternary complex
hIgM–SpA–mAb–toxin is sufficiently stable to be detected
in ELISA assays. Plausibly, therefore, soluble SpA could
bridge the Fc region of soluble hIgs to cell surface hIgs
coded by one or more of the 16 germline VHIII genes en-
coding SpA reactivity. Remarkably, up to 54% of human B
cells are capable of binding SpA (64), whereas VH families
J606 and S107 are expressed in only 10–20% of adult B lym-
phocytes of BALB/c mice (65–68) and are likely to bind
SpA. Therefore, it is not impossible that the binding of SpA
with hIgs could cause a boosting effect in humans similar to
the one that we described here for mice.
During an humoral immune response, an Ag is captured
by dendritic cells, macrophages, and Ag-specific B cells,
processed, and presented to Ag-specific T helper cells.
This cascade of events leads to Ab secretion. The secreted
Ag-specific Abs bind to the Ag, forming an heterogeneous
population of immune complexes. It has been proposed
that these complexes can cause a negative feedback on the
specific antibody response, as a result of the diversion of
Ags from their specific B cells, toward cells possessing Ig re-
ceptors, i.e., FcgR-expressing cells and RF-producing B
cells (69). In this scenario, the Ag-specific helper T cells
may activate B cells producing RF by intermolecular help.
The data presented in this paper suggest another mecha-
nism that might affect the immune response during an in-
fection process by IBP-secreting bacteria. As a result of the
presence of a soluble IBP, SpA for example, the Ab–Ag
complexes may be targeted to B cell IgMs that can bind
SpA. The SpA-binding B cells may thus present T cell
epitopes from the targeted immune complexes and stimu-
late the corresponding T cells and may be activated by an
intermolecular help mechanism. Although their specific
Ags may not necessarily be present in the medium, the tar-
geted B cells may nevertheless secrete their natural antibod-
ies. The specificities of the produced antibodies cannot be
identified a priori. However, they are likely to be large be-
cause the VH-reactive B cells are not bound by SpA via the
traditional antigen binding site. It is tempting to speculate
that this predicted diverting mechanism by an IBP may
help the bacteria to evade the immune response.1226 Boosting of Antigen Presentation by Immunoglobulin Binding Proteins
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